La Jolla Pharmaceutical Company (LJPC) Receives Notice Of Allowance For Patent Claims Covering Modified Pectin For Treatment Of Chronic Inflammation
2/20/2014 8:55:32 AM
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a notice of allowance for patent application number 13/888,158 covering methods of treating chronic inflammation using modified pectin. Specifically, the patent, which expires in 2025 without taking into account patent term extension, provides proprietary protection for methods of treating chronic inflammation by administration of modified pectin with a molecular weight greater than 25 kilodaltons.
Help employers find you! Check out all the jobs and post your resume.
comments powered by